Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
Status:
Recruiting
Trial end date:
2029-08-30
Target enrollment:
Participant gender:
Summary
There are more and more PARPi(PARP inhibitors) resistance for ovarian cancer patients after
previous use of PARP inhibitors. Basic studies have found that there is synergistic effect of
bevacizumab combined with PARPi. Therefore we designed the study to include 42 ovarian cancer
patients who had PARPi for at least half a year and then relapsed (platinum-sensitive,
previously 1-3 lines of chemotherapy). After getting complete remission or partial remission
with chemotherapy containing platinum and bevacizumab, fluzopanib and bevacizumab were used
for maintenance treatment. The progression-free survival, ORR, DCR, DoR, and safety were
evaluated based on RECIST V1.1.